Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Nutriband and Kindeva to Co-Develop Aversa Fentanyl Abuse-Deterrent Patch
Details : Nutriband is partnering with Kindeva to develop Aversa Fentanyl which combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.
Product Name : Aversa Fentanyl
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 13, 2025
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : U.S. Department of Health and Human Services
Deal Size : $129.0 million
Deal Type : Funding
Kindeva Secures $129M SNS Contract for Nerve Agent Antidote
Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.
Product Name : Duodote
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2025
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : U.S. Department of Health and Human Services
Deal Size : $129.0 million
Deal Type : Funding
Nutriband Signs Agreement with Kindeva for Abuse Deterrent Fentanyl Patch
Details : Kindeva will develop commercial manufacturing processes and clinical supplies for Aversa Fentanyl, integrating Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's fentanyl patch system.
Product Name : Aversa Fentanyl
Product Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2024
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Nutriband
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.
Product Name : Aversa
Product Type : Small molecule
Upfront Cash : Not Applicable
April 04, 2023
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Nutriband
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Diclofenac Epolamine
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Recipient : Virpax Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee.
Product Name : Epoladerm
Product Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2022
Lead Product(s) : Diclofenac Epolamine
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Recipient : Virpax Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Recipient : Viatris
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Breyna (Budesonide and Formoterol Fumarate Dihydrate), first approved generic version of AstraZeneca's Symbicort, a drug-device combination product, is indicated for certain patients with asthma or COPD and will be available in 160 /4.5 and 80/4.5 mcg do...
Product Name : Breyna
Product Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2022
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Recipient : Viatris
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Albuterol sulfate is used to treat or prevent bronchospasm in patients four years and older with reversible obstructive airway disease, such as asthma, and to prevent exercise-induced bronchospasm.
Product Name : Proventil HFA
Product Type : Small molecule
Upfront Cash : Undisclosed
March 16, 2021
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Recipient : Viatris
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Tentative Approval to Generic Version of Symbicort
Details : The U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first generic version of Symbicort based on an Abbreviated New Drug Application (ANDA).
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
March 09, 2021
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Recipient : Viatris
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BOL-DP-o-04
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : BOL Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Kindeva and BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products
Details : Under the agreement, Kindeva will develop novel formulations of BOL Pharma’s cannabinoid based drug products delivered by Kindeva’s metered-dose inhaler (MDI) technology.
Product Name : BOL-DP-o-04
Product Type : Small molecule
Upfront Cash : Undisclosed
December 01, 2020
Lead Product(s) : BOL-DP-o-04
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : BOL Pharma
Deal Size : Undisclosed
Deal Type : Agreement